The UK’s Medical Research Council (MRC) awarded £1.5m ($2.07m) to back a study investigating how changes in gene function in targeted brain cells lead to an improved understanding of how Alzheimer’s disease develops and unfolds. Led by the University of Exeter along with co-investigators at the UK DRI Centre at Imperial College London as well as the University of Essex and the University of Bristol, the study funds support investigations to understand how gene activity at the cellular level leads to the development of this insidious disease associated with aging. Imperial College London shares more about this important early-stage cellular-level research.
This chronic, neurodegenerative disorder affects nearly 30 million worldwide. There is no cure or real treatment to improve disease course. Some notable approvals over the last couple of years include a not widely covered approval by Chinese regulators involving Green Valley Pharma’s Oligomannate. Meanwhile, most recently, the U.S. Food and Drug Administration (FDA) controversial approval of Biogen’s Aduhelm led to an external investigation by Health and Human Services Office of Inspector General (OIG) reported ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).